Medical Incubator Japan

Name

Medical Incubator Japan

Legal name

株式会社Medicinalインキュベータ.jp

Website

https://medicalincubatorjapan.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910)

SIC

Investment Advice (6282)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Healthcare venture capital
• Biotech investment fund
• Pharmaceutical startup funding
• Medical device investment
• Digital health investing

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Core offering

Medical Incubator Japan is a Tokyo-based healthcare-focused venture capital firm that invests equity capital in domestic and international biotech, regenerative medicine, gene therapy, medical device, and digital health startups. It manages multiple limited partnership funds and provides hands-on commercialization support including IP strategy, fundraising, clinical development, regulatory affairs, and post-marketing activities to portfolio companies.

Product overview

Medical Incubator Japan is a healthcare-focused venture capital firm offering investment products including the MIJ Biotech-Global Investment Limited Partnership (international biotech investments), MIJ Biotech-Japan Investment Limited Partnership (Japanese investments), and the newer MIJ BG2 Limited Partnership (200 billion yen fund for drug loss elimination). The firm also provides operational support through the SSI Consortium for startup development from clinical stages through commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• MIJ Biotech-Global Investment Limited Partnership
• MIJ Biotech-Japan Investment Limited Partnership
• MIJ BG2 Limited Partnership
• SSI Consortium

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Bamburgh Capital LimitedcoreGTM or Marketing PartnerUK ecosystem partner for MIJ to identify investment opportunities. Through partnership with Bamburgh Capital, MIJ focuses on identifying investment opportunities in the UK healthcare innovation ecosystem.
• SSI Consortium (CareNet, ASKLEP, Pharma Information Network, Golden Child, Macromill)coreStrategic or Co-development PartnerConsortium providing one-stop support for healthcare startups from clinical development through market research, launch materials, marketing, and post-marketing surveillance. Established May 2018.
• 株式会社LinDocoreStrategic or Co-development PartnerSeed incubator established to build 'new business model for drug loss elimination' - developing and selling drugs in Japan that are being developed overseas but have no development plans in Japan. MIJ, CareNet, VKHD, and FHD all participated as capital partners.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• JAFCO: Japan's largest venture capital firm with a dedicated life sciences practice and historical biotech IPO track record. Directly comparable as a Japan-domiciled biotech/life sciences VC; multiple MIJ team members (Harada, Murai) joined from JAFCO.
• Mitsubishi UFJ Capital: Japanese VC affiliated with Mitsubishi UFJ Financial Group with a long-standing Life Science Investment Department. Highly comparable — Shigeru Yasue spent 20 years there co-founding the life science practice and achieved 13 exits.
• Catalys Pacific: Japan-based biotech-focused venture fund investing in first-in-class therapeutics globally with strong ties to Japanese pharma. Comparable scope and stage focus to MIJ, particularly around regenerative medicine and oncology.
• Beyond Next Ventures: Japan-based early-stage VC focused on deep tech and biotech with a hands-on incubation model. Comparable in size, team structure, and stage of investment; similar focus on university-derived and first-in-class life science assets.
• 4BIO Capital: UK-based specialist biotech VC investing in advanced therapies, gene therapy, and orphan diseases. Directly comparable as a co-investor with MIJ (led Cytospire's £61M Series A) and similar therapeutic focus.
• UTEC (University of Tokyo Edge Capital): Japanese deep-tech and life sciences VC affiliated with the University of Tokyo. Comparable as a Japan-based VC investing in university-originated biotech including regenerative medicine (similar to MIJ's Heartseed investment).
• Real Tech Holdings: Japan-focused deep tech VC with significant life sciences and biotech exposure. Comparable in stage, regional focus, and hands-on support model to MIJ's early-stage healthcare investing.
• Novo Holdings (Novo Seeds): Danish life sciences investor (parent of Novo Seeds) with a global biotech mandate. Directly comparable as a co-investor with MIJ in Hoba Therapeutics and as a sophisticated biotech-focused LP-style investor.

Broad incumbents

• Khosla Ventures: Large US venture firm with significant life sciences/healthcare investing across therapeutics, diagnostics, and digital health. Comparable as a co-investor in IgGenix Series B and as a broader incumbent in MIJ's competitive set for biotech deals.
• SR One (GSK): Corporate venture arm of GSK investing in early-stage biotech and therapeutics globally. Comparable as a larger, established pharma-affiliated life sciences investor operating in the same deal universe as MIJ.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medical Incubator Japan